Volume 10, Issue 5 (10-2012)                   IJRM 2012, 10(5): 465-472 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bonakdaran S, Mazloom Khorasani Z, Davachi B, Mazloom Khorasani J. The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo- controlled clinical trial. IJRM 2012; 10 (5) :465-472
URL: http://ijrm.ir/article-1-312-en.html
The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo- controlled clinical trial
Shokoufeh Bonakdaran * 1, Zahra Mazloom Khorasani2 , Behrooz Davachi3 , Javad Mazloom Khorasani4
1- Endocrine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran , bonakdaransh@mums.ac.ir
2- Endocrine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3- Department of Radiology, Radiology Center, Mashhad University of Medical Sciences, Mashhad, Iran
4- Imam Reza Hospital, Mashhad, Iran
Abstract:   (2920 Views)
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females of reproductive age. Insulin resistance is a frequent metabolic disturbance in PCOS. Vitamin D deficiency is a common problem. Accumulating evidence suggests that vitamin D has a role on insulin sensitivity so may contribute to reduction of hyperandrogenemia.
Objective: The aim was to determine the effects of vitamin D treatment in metabolic components and ovulation evidence in PCOS.
Materials and Methods: Fifty one untreated PCOS patients were randomly divided into three groups and treated with calcitriol, metformin, or placebo. Before and 3 months after treatment, ovulation evidence was assessed by ovarian trans abdominal sonography. Plasma fasting glucose, insulin, homeostasis model assessment insulin resistance (HOMA-IR), 25-hydroxyvitamin D, parathyroid hormone and androgen levels were measured before and after treatment. A 75gr glucose test was performed before and after treatment and two set of results was compared.
Results: Three patients did not continue this study. Only 11 patient (22.9%) had sufficient vitamin D levels (>30 ng/ml). Metformin caused a significant decrease in weight (p=0.027), insulin level (p=0.043), and insulin resistance (p=0.048). Systolic blood pressure and PTH significantly improved after calcitriol (p=0.029, p=0.009 respectively). An improvement in ovulation was detected after calcitriol and seven patients, without evidence of ovulation before treatment, illustrated ovulation after 3 months. Difference with calcitriol in ovulation was significant versus other two methods (p=0.02). Conclusion: Calcitriol treatment in PCOS may be prior to metformin in ovulation induction.
Keywords: PCOS, Ovulation, Vitamin D, Insulin resistance
Full-Text [PDF 341 kb]   (674 Downloads) |   |   Full-Text (HTML)  (302 Views)  
Type of Study: Original Article |
References
1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749. [DOI:10.1210/jc.2003-032046]
2. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47. [DOI:10.1093/humrep/deh098]
3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236. [DOI:10.1056/NEJMra041536]
4. McCarty MF. Poor vitamin D status may contribute to high risk for insulin resistance, obesity, and cardiovascular disease in Asian Indians. Med Hypotheses 2009; 72: 647-651. [DOI:10.1016/j.mehy.2008.12.031]
5. Gannage-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol 2009; 160: 965-968. [DOI:10.1530/EJE-08-0952]
6. Reis JP, von Muhlen D, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007; 30: 1549-1555. [DOI:10.2337/dc06-2438]
7. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007; 30: 980-986. [DOI:10.2337/dc06-1994]
8. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006; 114: 577-583. [DOI:10.1055/s-2006-948308]
9. Kotsa K, Yavropoulou MP, Anastasiou O, Yovos JG. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril 2009; 92: 1053-1058. [DOI:10.1016/j.fertnstert.2008.07.1757]
10. Rashidi B, Haghollahi F, Tehranian N, Shariat M, Zayerii F, Bagheri M, et al. Therapeutic effects of vitamin D and calcium in patients with polycystic ovary syndrome. J Fertil Infertil 2006; 7: 225-233.
11. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-654. [DOI:10.1016/0026-0495(94)90209-7]
12. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; CD003053.
13. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009; 161: 575-582. [DOI:10.1530/EJE-09-0432]
14. Wortsman J, Matsuoka LY, Chen TC, LU Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-693. [DOI:10.1093/ajcn/72.3.690]
15. Compston JE, Vedi S, Ledger JE, Webb A, Gazet JC, Pilkington TR. Vitamin D status and bone histomorphometery in grass obesity. Am J Clin Nutr 1981; 34: 2359-2363. [DOI:10.1093/ajcn/34.11.2359]
16. Mahmoudi T, Gourabi H, Ashrafi M, Yazdi RS, Ezabadi Z. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil Steril 2010; 93: 1208-1214. [DOI:10.1016/j.fertnstert.2008.11.031]
17. Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium+ vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 2007; 85: 54-59.
18. Tai K, Need AG, Horowitz M, Chapman IM. Glucose tolerance and vitamin D: effects of treating vitamin D deficiency. Nutrition 2008; 24: 950-956. [DOI:10.1016/j.nut.2008.04.009]
19. Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids 1999; 64: 430-435. [DOI:10.1016/S0039-128X(99)00012-4]
20. Racowsky C. The releasing action of calcium upon cyclic AMP-dependent meiotic arrest in hamster oocytes. J Exp Zool 1986; 239: 263-275. [DOI:10.1002/jez.1402390214]
21. Das M, Djahanbakhch O, Hacihanefioglu B, Saridogan E, Ikram M, Ghali L, et al. Granulosa cell survival and proliferation are altered in polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 881-887. [DOI:10.1210/jc.2007-1650]
22. Lou YR, Murtola T, Tuohimaa P. Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D (3), 1alpha, 25-dihydroxyvitamin D (3), dexamethasone and progesterone in prostate cancer cells. J Steroid Biochem Mol Biol 2005; 94: 151-157. [DOI:10.1016/j.jsbmb.2005.01.024]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb